Show simple item record

dc.contributor.authorRamsay, Craig R
dc.contributor.authorAdewuyi, Temitope E
dc.contributor.authorGray, Joanne
dc.contributor.authorHislop, Jenni
dc.contributor.authorShirley, Mark Df
dc.contributor.authorJayakody, Shalmini
dc.contributor.authorMacLennan, Graeme
dc.contributor.authorFraser, Cynthia
dc.contributor.authorMacLennan, Sara
dc.contributor.authorBrazzelli, Miriam
dc.contributor.authorN'Dow, James
dc.contributor.authorPickard, Robert
dc.contributor.authorRobertson, Clare
dc.contributor.authorRothnie, Kieran
dc.contributor.authorRushton, Stephen P
dc.contributor.authorVale, Luke
dc.contributor.authorLam, Thomas B
dc.date.accessioned2015-07-28T13:30:02Z
dc.date.available2015-07-28T13:30:02Z
dc.date.issued2015-07-01
dc.identifier.citationRamsay , C R , Adewuyi , T E , Gray , J , Hislop , J , Shirley , M D , Jayakody , S , MacLennan , G , Fraser , C , MacLennan , S , Brazzelli , M , N'Dow , J , Pickard , R , Robertson , C , Rothnie , K , Rushton , S P , Vale , L & Lam , T B 2015 , ' Ablative therapy for people with localised prostate cancer : a systematic review and economic evaluation ' , Health Technology Assessment , vol. 19 , no. 49 , pp. 1-524 . https://doi.org/10.3310/hta19490en
dc.identifier.issn1366-5278
dc.identifier.otherPURE: 52862619
dc.identifier.otherPURE UUID: fced5359-35f7-494e-88a9-2f0a1e9b14cd
dc.identifier.otherPubMed: 26140518
dc.identifier.otherScopus: 84934948929
dc.identifier.otherORCID: /0000-0003-1405-6964/work/61510997
dc.identifier.otherORCID: /0000-0003-4043-7349/work/84131300
dc.identifier.otherORCID: /0000-0002-1039-5646/work/98038493
dc.identifier.urihttp://hdl.handle.net/2164/4713
dc.descriptionThe research reported in this issue of the journal was funded by the HTA programme as project number 10/136/01. The contractual start date was in April 2012. The draft report began editorial review in October 2013 and was accepted for publication in April 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Acknowledgements We thank l the people recruited from the local UCAN for providing valuable consumer insight and advice through their participation as members of the project focus group: - Mark Emberton (Professor of Interventional Oncology), Damian Greene (consultant urologist), Axel Heidenreich (Professor and Director of Department of Urology), Christoph von Klot (specialist in brachytherapy), Roger Kockelbergh (BAUS chairman and Clinical Director of Urology) and Axel Merserburger (Deputy Clinical Director of Urology and Urologic Oncology) for providing their clinical expertise as members of the project advisory group - Edgar Paez (consultant urologist) and Gill Lawrence (Head of Radiotherapy Physics) for providing a list of staff time by grade and specialty involved in EBRT - Debbie Bennett (Radiotherapy Service Manager) for providing estimates for the expected number of uses for EBRT - Ian Pedley (clinical director/clinical oncologist) and Gill Lawrence for providing a list of all resource inputs relevant to brachytherapy - Steve Locks (Consultant Clinical Scientist in Radiotherapy) for providing a list of reusable equipment and consumables used during brachytherapy, along with their unit costs - Sue Asterling (urology research nurse) and Mark Kelly (Acting Divisional General Manager – Theatres) for providing a list of all resource inputs relevant to cryotherapy - Lara Kemp for providing secretarial support. The Health Services Research Unit is core funded by the Chief Scientist Office of the Scottish Government Health Directorates.en
dc.format.extent524
dc.language.isoeng
dc.relation.ispartofHealth Technology Assessmenten
dc.rights© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject10/136/01en
dc.subjectChief Scientist Office (CSO)en
dc.subject.lccRen
dc.titleAblative therapy for people with localised prostate cancer : a systematic review and economic evaluationen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Public Health, Health Services and Primary Careen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Academic Urology Uniten
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.3310/hta19490


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record